Eton Pharmaceuticals, Inc. ETON NASDAQ

Eton Pharmaceuticals, Inc. (ETON) has a negative trailing P/E of -154.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 32.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.65%, forward earnings yield 3.06%. PEG 0.52 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

• VALUE (35/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -154.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -0.65%).
• Forward P/E 32.7 — analysts expect a return to profitability with estimated EPS of $0.83 for FY2026.
• PEG Ratio 0.52 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
• Trailing Earnings Yield -0.65% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 3.06% as earnings recover.
• Analyst consensus target $25.00 (-7.8% downside) — slight downside risk — the market may be ahead of analyst expectations.

Overall SharesGrow Score: 38/100 with 1/7 criteria passed.